CMS0867.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, CMS (0867.HK) trades at a P/E of 14.10x, P/B of 1.20x, P/S of 2.50x, and a dividend yield of 3.38%.
Longitudinal percentile comparison: P/E sits at the 65th percentile over the trailing 10Y window (vs. 52nd percentile over 3Y); P/B sits at the 11th percentile over the trailing 10Y window (vs. 37th percentile over 3Y); P/S sits at the 12th percentile over the trailing 10Y window (vs. 31st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 47th percentile within its industry and the 61st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 3.65%, ranking at the 66th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 53.7 points — relying on either metric alone could be misleading. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Breaking down the total shareholder yield: 3.38% comes from cash dividends, with an implied ~0.27% from buybacks — a fairly balanced mix of both channels. CMS operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 0867 · SEHK: 0867 · 0867
Want the full picture on whether CMS (0867.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 14.10 | ||||||
| P/B (MRQ) | 1.20 | ||||||
| P/S (TTM) | 2.50 | ||||||
| Dividend Yield | 3.38% | ||||||
| Buyback + Div Yield | 3.65% |